
Feature|Articles|July 14, 2026
Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?
Author(s)Pearl Steinzor
Fact checked by: Maggie L. Shaw
CMS's enforcement surge has put every Medicaid Fraud Control Unit under review, but experts say the bigger driver of coverage loss may be red tape.
Advertisement
Advertisement
In January 2026, Minnesota received a letter from CMS announcing it would begin withholding $515 million in quarterly federal Medicaid payments, citing unresolved program integrity concerns.1 The state sued. A federal court dismissed the case on procedural grounds in April, and even after CMS accepted Minnesota's corrective action plan the following month, the withheld funds were not released.2 By May, CMS had gone further still, deferring $1.3 billion in federal Medicaid funding to the state—the largest deferral action in the agency's history.3
Related to this article

ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.

Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.

Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.

Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.

Working-age adults with private insurance are paying off medical debt, often draining savings, delaying care, or cutting back on necessities as a result.

Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.

Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.
Advertisement
Advertisement

